LNP-encapsulated mRNA delivery system for antigen-presenting cells, method for preparing same, and use thereof

By encapsulating mRNA with lipid nanoparticles (LNPs), the problems of cell damage and high cost caused by electroporation to antigen-presenting cells were solved, achieving efficient and low-toxicity mRNA delivery, promoting DC maturation and antigen presentation, and enhancing the scalability and clinical application potential of DC vaccines.

WO2026232459A1PCT designated stage Publication Date: 2026-11-12NANJING EOTO BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/093657
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-09
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing mRNA delivery methods, such as electroporation, cause cell damage to antigen-presenting cells and are costly and complex to operate, making it difficult to meet the need for simplification and cost reduction.

Method used

Lipid nanoparticles (LNPs) are used to encapsulate mRNA. A lipid nanoparticle system composed of ionizable cationic lipids, DSPC, cholesterol, and PEG2000 conjugated lipids is combined with microfluidic polymerization technology and purification steps to deliver mRNA directly to immature dendritic cells (iDCs) and avoid the electroporation process.

Benefits of technology

It achieves high transfection efficiency, low cytotoxicity, maintains DC viability and maturation capacity, promotes effective antigen presentation, reduces production costs and operational complexity, and enhances the scalability and clinical applicability of DC vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2025093657_12112026_PF_FP_ABST
    Figure CN2025093657_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the field of biopharmaceutical technology, and in particular, to an LNP-encapsulated mRNA delivery system for antigen-presenting cells, a method for preparing same, and use thereof. The LNP-encapsulated mRNA delivery system comprises an LNP-encapsulated mRNA encoding a tumor-associated antigen. The LNP comprises an SM102 ionizable cationic lipid, DSPC, cholesterol, and a PEG2000-conjugated lipid. The LNP-encapsulated mRNA delivery system in the present invention has high mRNA delivery efficiency and low cytotoxicity, and is capable of inducing the maturation of DC cells. DC cells bearing LNP-encapsulated mRNA are used to effectively activate anti-tumor immune responses, thereby facilitating the development and application of DC vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

LNP-encapsulated mRNA delivery system for antigen-presenting cells, its preparation method and application Technical Field

[0001] This application belongs to the field of biomedical technology, specifically relating to an LNP-encapsulated mRNA delivery system for antigen-presenting cells, its preparation method, and its application. Background Technology

[0002] Cancer immunotherapy has become a transformative strategy in oncology, leveraging the body's own immune system to recognize and eliminate tumor cells. Among emerging strategies, dendritic cell (DC) vaccines show significant promise due to the unique role of DCs as specialized antigen-presenting cells (APCs), triggering nascent T cells and coordinating adaptive immunity. DC vaccines have been at the forefront of immunotherapy research, demonstrating the potential for potent T-cell responses against tumor antigens, thereby inducing durable anti-tumor immunity. These vaccines utilize the natural ability of DCs to process and deliver antigens, which has been extensively documented in preclinical and clinical trials, highlighting their importance in the development of personalized cancer therapies.

[0003] Compared to DNA, peptide, or protein-based methods, mRNA-loaded DC vaccines exhibit significant advantages. Unlike DNA vaccines, mRNA vaccines do not compromise genome integration and achieve transient antigen expression, thus reducing safety concerns while allowing for rapid manufacturing and scalability. Compared to peptides, mRNA encodes full-length tumor antigens, enabling endogenous processing and presentation in both MHC classes, thereby expanding epitope coverage. Furthermore, mRNA allows for the simultaneous delivery of multiple antigens and immunomodulatory molecules, enhancing immune activation, which is beneficial for targeting tumor heterogeneity and enhancing immunogenicity. While protein-based vaccines are stable, they typically fail to elicit a robust CD8+ T cell response due to low cross-presentation efficiency. Compared to peptide or protein vaccines, the mRNA approach is not limited by MHC and can stimulate a broader immune response by inducing CD4+ and CD8+ T cell activation. Rapid translation of mRNA in the DC cytoplasm ensures high antigen yield, positioning it as a superior model for DC vaccine development.

[0004] Electroporation remains the primary method for delivering mRNA into dendritic cells (DCs) in vitro, with transient permeation of the cell membrane to facilitate mRNA uptake. Electroporation is highly regarded for its ability to achieve high transfection efficiency, ensuring robust antigen expression. However, this method has significant drawbacks: (1) cellular stress, impairing viability and function; (2) high costs associated with specialized equipment and reagents; and (3) logistical complexity, requiring cell collection, post-electroporation culture, and the inability to directly cryopreserve electroporated cells, which complicates the logistical aspects of vaccine manufacturing. These limitations underscore the need for a novel, simplified mRNA delivery method that maintains cell integrity and reduces overall production costs. Summary of the Invention

[0005] 1. The problem to be solved

[0006] The purpose of this invention is to provide an LNP-encapsulated mRNA delivery system for antigen-presenting cells, its preparation method, and its application, so as to solve the drawbacks of current mRNA delivery methods.

[0007] 2. Technical Solution

[0008] To solve the above problems, the technical solution adopted in this application is as follows:

[0009] This application provides an LNP-encapsulated mRNA (mRNA-LNP) delivery system for antigen-presenting cells, the system comprising lipid nanoparticles (LNPs) and at least one mRNA encoding a tumor-associated antigen (TAA), the mRNA being encapsulated in the lipid nanoparticles (LNPs).

[0010] As a preferred technical solution for the mRNA-LNP delivery system, the above-mentioned lipid nanoparticles (LNPs) include ionizable cationic lipids, DSPC, cholesterol, and PEG2000 conjugated lipids.

[0011] As a preferred technical solution for the mRNA-LNP delivery system, the molar ratio of the above-mentioned ionizable cationic lipids, DSPC, cholesterol and PEG2000 conjugated lipids is 50:10:38.5:1.5.

[0012] As a preferred technology for mRNA-LNP delivery systems, the aforementioned ionizable cationic lipids are selected from SM102, DLin-MC3-DMA, A15-1, or other similar compounds. Ionizable cationic lipids are used to adjust the lipid charge density, nanoparticle size, and stability of the prepared lipid nanoparticles (LNPs).

[0013] As a preferred technical solution for the mRNA-LNP delivery system, the aforementioned ionizable cationic lipid is selected from SM102.

[0014] As a preferred technology for mRNA-LNP delivery systems, the aforementioned lipid components can be modified by replacing certain lipid components. For example, PEGylated lipids, neutral lipids, or other lipid derivatives can be used to improve particle stability, cellular uptake, or circulating half-life. For instance, using cholesterol derivatives such as delta-lactone can enhance the biocompatibility and efficacy of LNPs.

[0015] As a preferred technology for mRNA-LNP delivery systems, the average particle size of the LNPs loaded with mRNA is ~70 nm, and the particle size range of the LNPs is 50–100 nm.

[0016] As a preferred technical solution for the mRNA-LNP delivery system, the tumor-associated antigen (TAA) is selected from one or more of mucin 1 (MUC-1), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), or Wilms tumor 1 (WT1).

[0017] As a preferred technology for mRNA-LNP delivery systems, the tumor-associated antigen (TAA) is selected from three of the following: mucin 1 (MUC-1), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), or Wilms tumor 1 (WT1).

[0018] As a preferred technical solution for the mRNA-LNP delivery system, the aforementioned mRNA-LNP delivery system further includes a cryoprotectant selected from one or more of sucrose, thioglycolate, glucose, or glycerol. The cryoprotectant stabilizes the LNP formulation during freeze-drying or long-term storage at low temperatures. The choice of cryoprotectant may depend on the specific storage conditions of the LNP and the desired stability profile.

[0019] As a preferred technical solution for the mRNA-LNP delivery system, the cryoprotectant is preferably 10% sucrose.

[0020] This application also provides a method for preparing the above-mentioned mRNA-LNP delivery system, the method comprising the following steps:

[0021] Ionizable cationic lipids, DSPC, cholesterol, and PEG2000 conjugated lipids were dissolved in ethanol at a molar ratio to form an organic phase;

[0022] The mRNA was placed in sodium acetate buffer to form an aqueous phase;

[0023] An mRNA-LNP delivery system was prepared by combining an organic phase and an aqueous phase at a volume ratio of 3:1 using microfluidic polymerization technology, with the total flow rate maintained at 6 mL / min.

[0024] As a preferred technical solution for the preparation method of the mRNA-LNP delivery system, the above preparation method further includes purification and refining, specifically including:

[0025] After the nanoparticles are formed, the LNPs are dialyzed three times consecutively using sterile PBS that does not contain divalent cations. The dialysing uses a 3.5 kDa molecular weight cutoff (MWCO) dialysis cartridge to remove low molecular weight impurities and ensure that the final LNP delivery system is free of solvents or uncoated substances.

[0026] After dialysis, the solution was centrifuged and ultrafiltered using a 30 kDa MWCO filter; this step further refines the LNPs, increases their concentration, and ensures that the final mRNA-LNP formulation meets the required specifications.

[0027] As a preferred technical solution for the preparation method of the mRNA-LNP delivery system, the above preparation method also includes adding 10% sucrose.

[0028] This application also provides the application of the above-mentioned mRNA-LNP delivery system in the preparation of mRNA-loaded antigen-presenting cells.

[0029] As a preferred technical solution for the application, the antigen-presenting cells are dendritic cells (DCs).

[0030] As a preferred technical solution for the application, the above application includes: adding an mRNA-LNP delivery system (lipid nanoparticles encapsulating mRNA) to cultured immature dendritic cells (iDCs).

[0031] As a preferred technical solution for the application, immature dendritic cells (iDCs) are co-cultured with the mRNA-LNP delivery system for 18–20 h.

[0032] As a preferred technical solution for the application, the amount of mRNA-LNP delivery system added is 0.5 to 2.0 μg of each tumor-associated antigen (TAA) based on the encapsulated mRNA.

[0033] As a preferred technical solution for the application, the amount of mRNA-LNP delivery system added is 1.0 μg of each tumor-associated antigen (TAA) based on the encapsulated mRNA.

[0034] As a preferred technical solution for the application, the amount of mRNA-LNP delivery system added is 1.0 μg each of mucin 1 (MUC-1), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), or Wilms tumor 1 (WT1) based on the encapsulated mRNA.

[0035] This application also provides a method for preparing mRNA-loaded dendritic cells (DCs), which includes adding the above-mentioned mRNA-LNP delivery system (lipid nanoparticles encapsulating mRNA) to cultured immature dendritic cells (iDCs).

[0036] As a preferred technical solution of the above method, the amount of mRNA-LNP delivery system added is 0.5 to 2.0 μg of each tumor-associated antigen (TAA) based on the encapsulated mRNA.

[0037] As a preferred technical solution of the above method, the amount of mRNA-LNP delivery system added is 1.0 μg of each tumor-associated antigen (TAA) based on the encapsulated mRNA.

[0038] As a preferred technical solution of the above method, the amount of mRNA-LNP delivery system added is 1.0 μg each of mucin 1 (MUC-1), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), or Wilms tumor 1 (WT1) based on the encapsulated mRNA.

[0039] This application also provides mRNA-loaded DC cells prepared by the above-described method for preparing mRNA-loaded DC cells.

[0040] This application also provides the application of the above-mentioned mRNA-loaded DC cells in the preparation of DC vaccines.

[0041] This application also provides a DC vaccine comprising the above-described mRNA-loaded DC cells.

[0042] 3. Beneficial effects

[0043] Compared with the prior art, the advantages of this application are as follows:

[0044] (1) This invention discloses a method for delivering tumor-associated antigens (TAAs) to dendritic cells (DCs) in vitro using lipid nanoparticles (LNPs)-encapsulated mRNA. In this method, LNPs are added directly to cultures of immature DCs (iDCs) without the need for cell collection and complex electroporation procedures. The iDCs are incubated with the LNP delivery system for 18 hours, during which time the encapsulated mRNA is efficiently delivered into the cells. This method offers transformative advantages: (a) high transfection efficiency without membrane disruption; (b) low cytotoxicity, maintaining DC viability and activation capacity; (c) actively promoting DC maturation, a key step in effective antigen presentation; and (d) functional versatility, as mRNA-loaded DCs elicit effective antigen-specific T cell responses. By eliminating the electroporation-dependent bottleneck, this method enhances scalability and clinical applicability, advancing DC vaccine platforms for cancer immunotherapy.

[0045] (2) This invention provides a lipid nanoparticle (LNP) delivery technology based on SM102 (ionizable cationic lipid) encapsulating mRNA. This technology can efficiently deliver mRNA to dendritic cells (DCs) without significantly negatively affecting cell viability. Compared with electroporation, the method of this invention has significant advantages in terms of faster operation and lower cost. More importantly, the LNP can effectively induce DC maturation, thereby reducing dependence on expensive exogenous maturation cytokine mixtures. At the same time, DCs loaded with mRNA-LNP can significantly activate anti-tumor immune responses, providing a novel preparation scheme with translational potential for the clinical application of DC vaccines. Attached Figure Description

[0046] Figure 1 shows the flow cytometry analysis results of eGFP expression after iDC and LNP (mRNA-eGFP) were co-cultured for 18 hours.

[0047] Figure 2 shows the comparative analysis results of cell viability after iDC was co-cultured with different treatment groups of LNP (mRNA-TAAs) for 18 hours.

[0048] Figure 3 shows the comparative analysis results of cell apoptosis after iDC was co-cultured with different treatment groups of LNP (mRNA-TAAs) for 18 hours.

[0049] Figure 4 shows the immunocytochemical (ICC) analysis results of TAA expression after iDC and LNP (mRNA-TAAs) were co-cultured for 18 hours.

[0050] Figure 5 shows the analysis results of DC maturation-related surface marker expression after 18 hours of co-culturing iDC with LNP (mRNA-TAAs).

[0051] Figure 6 shows the analysis results of expression levels and chemotactic ability of DC migration-related surface markers after 18 hours of co-culturing iDC with LNP (mRNA-TAAs).

[0052] Figure 7 shows the analysis results of T cell activation marker expression after co-culturing DC-loaded LNP-encapsulated mRNA (mRNA-TAAs) with T cells for 72 hours.

[0053] Figure 8 shows the analysis results of the secretion of interferon-γ (IFN-γ) levels after T cells were co-cultured with DC-loaded LNP-encapsulated mRNA (mRNA-TAAs) for 72 hours.

[0054] Figure 9 shows the analysis results of T cell viability and proliferation after co-culturing DC-loaded LNP-encapsulated mRNA (mRNA-TAAs) with T cells for 72 hours. Detailed Implementation

[0055] The present application will be further described below with reference to specific embodiments.

[0056] The following embodiments are intended to illustrate the technical solutions of the present invention more specifically, so that those skilled in the art can understand and implement the present invention, but should not be construed as limiting the scope of protection of the present invention. The claims should be used as the basis for defining the scope of protection of the present invention.

[0057] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood in the scientific field. Generally, the scientific terms used in this invention are well-known and typical in the art. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer are followed. Reagents or instruments whose manufacturers are not specified are all commercially available products.

[0058] As used herein, the term “about” is used to provide flexibility and imprecision in relation to a given term, measure, or value. Those skilled in the art can readily determine the degree of flexibility for a particular variable. Concentration, quantity, and other numerical data may be presented herein in a range format. It should be understood that such a range format is used only for convenience and brevity and should be flexibly interpreted to include not only the numerical values ​​explicitly stated as the limits of the range, but also all individual numerical values ​​or subranges covered within the range, as if each numerical value and subrange were explicitly stated. For example, a numerical range of about 1 to about 4.5 should be interpreted to include not only the explicitly stated limits of 1 to 4.5, but also individual numbers (such as 2, 3, 4) and subranges (such as 1 to 3, 2 to 4, etc.). The same principle applies to ranges that describe only a single numerical value, such as “less than about 4.5,” which should be interpreted to include all the values ​​and ranges described above. Furthermore, this interpretation should apply regardless of the breadth of the range or characteristic described.

[0059] As used in this application, the term "and / or" includes any and all combinations of one or more of the associated listed items. The term "at least one of..." is intended to be synonymous with "one or more of...". For example, "at least one of A, B, and C" explicitly includes only A, only B, only C, and combinations thereof.

[0060] As used in this application, SM102 is an ionizable lipid with the chemical name (4-(N,N-dimethylamino)butyric acid)-2,2-dimethyl-propyl(6-oxo-6-((2-((2,5-dioxo-2,5-dihydro-1H-pyrrolo-1-yl)methoxy)ethoxy)hexyl) ester. Under physiological pH conditions, it is electrically neutral, but in acidic environments (such as endosomes), it can be protonated and acquire a positive charge. This unique pH-responsive characteristic allows it to exhibit different pH responses in various physiological environments. Similar properties. In the LNP system, SM-102 plays a crucial role. It binds to negatively charged mRNA through electrostatic interactions, helping to condense and encapsulate the mRNA within the LNP, thus protecting it from nuclease degradation. Simultaneously, after cellular uptake of LNP, the acidic environment of the endosome causes SM-102 to protonate, enhancing the interaction between the LNP and the endosome membrane, promoting the escape of the LNP from the endosome, and releasing the mRNA into the cytoplasm to initiate subsequent translation.

[0061] The detection scheme used in this application is as follows:

[0062] Cell counting and viability detection: The cell count was performed using a Cellometer K2 fluorescence cell counter.

[0063] Apoptosis detection: Analysis was performed using the FITC Annexin V Apoptosis Detection Kit (containing PI).

[0064] eGFP expression was detected by flow cytometry.

[0065] Tumor-associated antigen (TAAs) expression detection: Identification was performed using immunocytochemistry (ICC).

[0066] Cell surface marker detection: Analysis was performed using flow cytometry.

[0067] Migration performance was evaluated using Transwell experiments.

[0068] T cell activation status analysis: After co-culturing DC cells and T cells at a ratio of 1:10 for 72 hours, the following indicators were detected: (a) T cell activation markers: detected by flow cytometry; (b) IFN-γ secretion level: measured by ELISA and ELISPOT enzyme-linked immunospot assay; (c) T cell proliferation capacity: assessed by MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide).

[0069] The instruments and reagents used in this application are as follows:

[0070] Counter, Brand: Revvity, Item No.: CMT-K2-MX-150;

[0071] Apoptosis kit, brand: Biolegend, catalog number: 640914;

[0072] Flow cytometer, brand: Beckman, catalog number: C01161 (CytoFLEX S V4-B4-R3-I2);

[0073] TAA antibodies, brand: Abcam (MUC1: ab45167; NY-ESO-1: ab139339; WT-1: ab89901);

[0074] Flow cytometry antibodies, brand: Biolegend (FITC anti-human CD80 Antibody: 375406; PE anti-human CD86 Antibody: 374206; APC anti-human CD40 Antibody: 334310; PerCP / Cyanine 5.5 anti-human HLA-A, B, C: 311422; PE / Cyanine 7 anti-human CD54 Antibody: 353116; Brilliant Violet 421) TM anti-human CD83 Antibody: 305324; APC / Cyanine7 anti-human CD197 (CCR7) Antibody: 353212; Brilliant Violet 510 TM anti-human CD184 (CXCR4) Antibody: 306536; FITC anti-human CD3 Antibody: 300406; APC anti-human CD69 Antibody: 310910; PE anti-human CD25 Antibody: 302606);

[0075] Human IFN-γELISA Set, Brand: BD Biosciences, Catalog No.: 555142;

[0076] ELISPOT Human IFN-g ELISPOT Set, Brand: BD Biosciences, Product Code: 551849;

[0077] MTT reagent kit, brand: AffiGen, catalog number: AFG-BV-0473;

[0078] Transwell, brand: Corning, item number: 3374.

[0079] In this application, tumor-associated antigens (TAAs) include, but are not limited to, mucin 1 (MUC-1), New York esophageal squamous cell carcinoma-1 (NY-ESO-1), and Wilms' tumor protein 1 (WT1). These antigens are widely expressed in various solid tumors and hematologic malignancies and have strong immunogenicity.

[0080] This application does not limit the method of mRNA preparation. As an example: mRNA is used to design and encode tumor-associated antigens (TAAs), which are synthesized via in vitro transcription (IVT). The specific steps are summarized below:

[0081] (I) Template Construction:

[0082] Based on the full-length or partial gene sequence encoding human MUC-1, NY-ESO-1, or WT1, a linear DNA template containing the T7 promoter is constructed. To improve translation efficiency and mRNA stability, the template may include 5' and 3' untranslated regions (UTRs) and a poly(A) tail sequence consisting of 100-120 adenosine residues.

[0083] (II) In vitro transcription reaction:

[0084] Transcription is performed using T7 RNA polymerase in an appropriate reaction buffer. To achieve co-transcriptional capping, it is best to add a capping analog such as CleanCap or ARCA, or to perform enzymatic digestion and capping after transcription.

[0085] (III) Modification and purification:

[0086] Synthesized mRNA can be produced by adding nucleosides (such as pseudouridine (Ψ) or 5-methylcytidine (m)). 5 C)) Further modifications are made to improve stability and reduce immunogenicity. After transcription, the template DNA is removed using DNase I, and the obtained mRNA is then purified using chromatography, high-performance liquid chromatography, or magnetic beading to obtain high-purity mRNA.

[0087] (IV) Quality Control Testing:

[0088] The integrity and purity of mRNA were assessed by agarose gel electrophoresis or using a bioanalyzer. Quantification was performed by ultraviolet spectrophotometry or fluorescent dye-based methods (such as the RiboGreen assay).

[0089] In this application, a DC maturation induction mixture was added to the positive control group. The mixture included: interferon-gamma (IFN-γ, 20 ng / mL), polyinosinic-polycytidylic acid (Poly I:C, 20 μg / mL), resiquimod (R848, 2.5 μg / mL), and prostaglandin E2 (PGE2, 1 μg / mL), with an induction time of 18 to 20 hours. After cell collection, mRNA encoding MUC-1, NY-ESO-1, and WT-1 antigens (1 μg / 1 × 10⁻⁶) was introduced via electroporation. 6 (1,000 cells, Lonza 4D-Nucleofector). The negative control group was cultured for the same amount of time without the addition of this maturation mixture.

[0090] As used herein, peripheral blood mononuclear cells (PBMCs) are obtained from peripheral blood using the Ficoll-Hypaque gradient centrifugation method, a method known to those skilled in the art. As an example, this application further elaborates on this method as follows:

[0091] Draw blood sample from blood bag using a 50mL syringe and dilute with DPBS to 30-35mL. Add 15mL of Ficoll to a new 50mL centrifuge tube using a pipette, and slowly add the diluted blood sample to the Ficoll. Centrifuge at 800g for 20min at room temperature, with a 1% increase and 0% decrease. After centrifugation, discard the plasma layer and slowly aspirate the white membrane layer of PBMCs to a new centrifuge tube using a pipette. Add DPBS to 45mL and centrifuge at 300g for 5min at room temperature, with a 1% increase and 1% decrease. Discard the supernatant, resuspend the cells in DPBS, add DPBS to 45mL, and centrifuge at 1300rpm for 5min at room temperature.

[0092] As used in this article, the separated CD16 - CD14 + Peripheral blood mononuclear cells are CD16 cells in peripheral blood mononuclear cells. - CD14 + Monocytes, which can be isolated using kits, such as the MojoSort Human CD14 Selection Kit (EasySep), are used as an example. TM Human Monocyte Isolation Kit, STEMCELL TM ).

[0093] Example 1

[0094] This embodiment provides an LNP-encapsulated mRNA delivery system for antigen-presenting cells and a method for its preparation.

[0095] In this embodiment, the lipid nanoparticles (LNPs) encapsulating Cap1-modified mRNA are produced using proprietary microfluidic polymerization technology. Synthesized on a platform, this technology allows for precise control of key parameters such as the nitrogen-to-phosphorus (N / P) ratio, particle size, and uniformity. This method ensures optimal encapsulation efficiency and controlled mRNA release profiles.

[0096] In this embodiment, the ionizable lipid nanoparticle formulation consists of the following lipids in a precise molar ratio: SM102 (ionizable cationic lipid), DSPC (1,2-distearate-sn-glycerol-3-phosphocholine), cholesterol, and PEG2000 conjugated lipid, in a specific ratio of 50:10:38.5:1.5 (molar:molar); these lipids are dissolved in ethanol, and the final lipid concentration is 25 mM.

[0097] In this embodiment, the concentration of mRNA in 25mM sodium acetate buffer (pH 5.0) is 0.1 mg / mL to maintain the stability of the nucleic acid and prevent degradation during encapsulation. This buffer composition is designed to provide optimal conditions for maintaining the integrity of the mRNA and to promote the effective encapsulation of lipid nanoparticles.

[0098] In this embodiment, the organic lipid phase and the aqueous mRNA phase are separated by... The converging microchannel structure within the chamber is integrated. The total flow rate is maintained at 6 mL / min, with a volume ratio of 3:1 (aqueous phase: organic phase). This design facilitates rapid nanoprecipitation of LNPs due to the electrostatic interaction between ionizable lipids and negatively charged mRNA. The resulting nanoparticles are formed under controlled conditions, ensuring a uniform particle size distribution and high encapsulation efficiency.

[0099] In one embodiment of this application, purification and refining are also included:

[0100] After nanoparticle formation, the LNPs were dialyzed three times consecutively using sterile, dication-free PBS (phosphate-buffered saline) to remove residual organic solvents and uncoated mRNA. Dialysis was performed using a 3.5 kDa molecular weight cutoff (MWCO) dialysis cartridge to remove low-molecular-weight impurities, ensuring that the final LNP delivery system was free of solvents and uncoated substances.

[0101] To further concentrate and purify the LNPs, the solution was subjected to centrifugal ultrafiltration using a 30 kDa MWCO filter. This step further refined the LNPs, increasing their concentration and ensuring the final mRNA-LNP formulation met the required specifications. The final concentration of the mRNA-LNP formulation was determined to be 50 μg / mL. Optional addition of 10% sucrose as a cryoprotectant was made to improve the stability of the nanoparticles during storage, especially during freeze-drying or long-term storage. The role of sucrose is to protect the LNP structure and prevent aggregation during freezing.

[0102] (1) Encapsulation efficiency and mRNA quantification analysis

[0103] This application uses a biphase... Encapsulation efficiency (EE) was rigorously quantified using fluorescence detection. Specifically, lipid nanoparticles (LNPs) were first lysed using TE buffer (pH 8.0) containing 1% Triton-X-100 to release encapsulated mRNA, while free mRNA was separated using detergent-free TE buffer. Fluorescence intensity was measured at 485 nm excitation and 528 nm emission wavelengths using a high-sensitivity multimode microplate reader, and a standard curve was established based on pre-encapsulated mRNA standards (0.1–2.0 μg / mL) to ensure data accuracy.

[0104] Encapsulation efficiency (EE) is calculated using the following formula:

[0105] Experimental data show that the encapsulation rate of this delivery system exceeds 92%, confirming its efficient and stable mRNA encapsulation performance.

[0106] (2) High-level characterization of the mRNA-LNP delivery system

[0107] (I) Particle size and distribution characteristics analysis

[0108] The particle size distribution of LNPs was characterized using a temperature-controlled nanoparticle size analysis system (at 25℃) and dynamic light scattering (DLS). LNPs were suspended in PBS (refractive index 1.33) and PBS solution containing 10% sucrose (refractive index 1.38), respectively. Forty data acquisitions were performed for each sample, with four technical replicates per batch. The results showed that the average hydrodynamic diameter of the LNPs was ~70 nm, and the polydispersity index (PDI) was less than 0.06.

[0109] (II) mRNA integrity verification

[0110] Capillary electrophoresis was used to assess the integrity of the encapsulated mRNA, confirming that over 88% of the mRNA retained its full-length structure. Non-denaturing agarose gel electrophoresis further validated this result, showing intact migration bands.

[0111] (3) Stability and large-scale production capacity

[0112] (I) Stability Study

[0113] This invention confirms that lipid nanoparticles (LNPs) maintain excellent stability when stored at -80°C for more than six months, with particle size variation and encapsulation efficiency (EE) fluctuations both less than 5%.

[0114] (II) Validation for large-scale production

[0115] Batch production validation in accordance with Good Manufacturing Practice (GMP) requirements was conducted using at least two independent production batches. The relative standard deviation (RSD) of key quality attributes was less than 3%, demonstrating the excellent process reproducibility and scalability of the delivery system.

[0116] Example 2

[0117] This embodiment provides the preparation and culture of dendritic cells (DCs).

[0118] The isolated CD16-CD14+ monocytes were resuspended in culture medium, and the final cell concentration was adjusted to 1×10⁻⁶. 6 Cells / mL. Cells were seeded in 24-well plates (1 mL per well), T175 flasks (35 mL per flask), or T75 flasks (18 mL per flask) and cultured in a 37°C, humidified incubator. The culture medium used was AIM-V, supplemented with the following cytokines: interleukin-4 (IL-4, 100 ng / mL), granulocyte-macrophage colony-stimulating factor (GM-CSF, 100 ng / mL), and interleukin-15 (IL-15, 100 ng / mL).

[0119] After 48 hours of culture, lipid nanoparticles (LNPs) encapsulating messenger RNA (mRNA) were directly added to the cultured immature dendritic cells (iDCs). The LNP-mRNA used encoded one of the following: (a) enhanced green fluorescent protein (eGFP), at a dosage of 1 × 10⁻⁶ mRNA. 6 (a) 1.0, 2.5, 5.0 or 7.5 μg per cell; (b) one or more tumor-associated antigens (TAAs) at a dosage of 1 × 10⁻⁶ cells / cell. 6 0.5, 1.0 or 2.0 μg of each TAA per cell; the above dosages refer to the mass of the encapsulated mRNA.

[0120] After adding LNP-mRNA, cells were cultured for another 18 to 20 hours before being harvested.

[0121] Example 3

[0122] This embodiment provides the detection of eGFP expression after LNP-encapsulated eGFP mRNA is loaded into immature dendritic cells (iDCs).

[0123] This embodiment aims to verify whether lipid nanoparticles (LNPs) encapsulating mRNA encoding enhanced green fluorescent protein (eGFP) can be effectively delivered to immature dendritic cells (iDCs) and drive their successful expression.

[0124] In this embodiment, iDCs were derived from human peripheral blood mononuclear cells and were obtained by differentiation and culture for 48 hours under the combined induction conditions of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and interleukin-15 (IL-15).

[0125] In this embodiment, different doses (1.0 μg, 2.5 μg, 5.0 μg and 7.5 μg based on mRNA encapsulation amount) of LNP-eGFP mRNA solution were added to iDCs, and the incubation time was set to 18 hours.

[0126] eGFP expression was detected by flow cytometry. Further quantitative analysis of eGFP expression was performed using flow cytometry, with a focus on the expression efficiency at the 18-hour incubation time point.

[0127] After co-culturing iDCs with LNP (mRNA-eGFP) for 18 hours, the flow cytometry analysis results of eGFP expression are shown in Figure 1. Figure 1A shows the proportion of eGFP-positive cells (eGFP+) under different mRNA dosage conditions: 1.0 μg group: 36.5%; 2.5 μg group: 69.2%; 5.0 μg group: 79.3%; 7.5 μg group: 94.7%. Figure 1B shows the eGFP fluorescence intensity (mean fluorescence intensity, MFI) in each group of cells: 1.0 μg group: 6099; 2.5 μg group: 12529; 5.0 μg group: 16299; 7.5 μg group: 29033.

[0128] These results further validate that the LNP platform used in this application has excellent mRNA delivery efficiency and expression capacity in immature dendritic cells, and its effect is significantly positively correlated with the dose of mRNA used.

[0129] Example 4

[0130] This embodiment provides the detection of DC viability after LNP-encapsulated mRNA is loaded into immature dendritic cells (iDCs).

[0131] (1) Effect of single mRNA loaded with LNP on DC viability

[0132] LNPs encoding MUC-1 mRNA were co-incubated with iDCs for 18 hours at different doses (0.5 μg, 1.0 μg, and 2.0 μg, based on the encapsulated mRNA), and cell viability was detected.

[0133] The test results are shown in Figure 2A. The DC activity in the control group was 89.1%. The cell viability in the treatment groups were as follows: 0.5 μg group: 86.25%; 1.0 μg group: 83.35%; 2.0 μg group: 79.5%.

[0134] These results indicate that, despite a slight decrease in cell viability, the LNP delivery system exhibits good overall biocompatibility within the experimental dosage range.

[0135] (2) Effect of LNP on DC viability after mixed delivery of three mRNAs

[0136] Three different LNPs were used to encapsulate mRNAs encoding three antigens: MUC-1, NY-ESO-1, and WT-1 (i.e., each LNP loaded only one mRNA, and the total mRNA doses for each TAA were 0.5 μg, 1.0 μg, and 2.0 μg, respectively). The LNPs were then co-incubated with iDCs for 18 hours, and cell viability was detected.

[0137] The test results are shown in Figure 2B: 0.5μg group: 83.05%; 1.0μg group: 78.7%; 2.0μg group: 70.65%.

[0138] Data shows that even under conditions of co-delivery of three antigens, DCs still maintain a high level of viability, demonstrating that the system can deliver multiple antigens simultaneously without significantly impairing cell function.

[0139] Example 5

[0140] This embodiment provides the detection of apoptosis in dendritic cells (iDCs) after LNP-encapsulated mRNA is loaded into immature dendritic cells (iDCs).

[0141] (1) Effect of single mRNA loaded with LNP on DC apoptosis

[0142] LNPs encoding MUC-1 mRNA were co-incubated with iDC at different doses (0.5 μg, 1.0 μg, 2.0 μg) for 18 hours, and the proportion of early and late apoptosis was detected by Annexin V / PI double staining.

[0143] The test results are shown in Figure 3:

[0144] Early apoptosis: Control group: 3.0%; 0.5μg group: 3.9%; 1.0μg group: 3.2%; 2.0μg group: 4.0%;

[0145] Late apoptosis: Control group: 2.3%; 0.5 μg group: 3.4%; 1.0 μg group: 4.1%; 2.0 μg group: 4.8%.

[0146] (2) Effects of LNP co-delivery of three mRNAs on DC apoptosis

[0147] Three LNPs encoding mRNA of MUC-1, NY-ESO-1 and WT-1 were co-delivered, with total TAA doses of 0.5 μg, 1.0 μg and 2.0 μg, respectively. Apoptosis was detected after 18 hours of incubation.

[0148] The test results are shown in Figure 3:

[0149] Early apoptosis: Control group: 3.0%; 0.5μg group: 4.9%; 1.0μg group: 5.1%; 2.0μg group: 8.1%;

[0150] Late apoptosis: Control group: 2.3%; 0.5 μg group: 5.3%; 1.0 μg group: 6.0%; 2.0 μg group: 8.9%.

[0151] Overall, although the proportion of DC apoptosis increased under high-dose and multi-antigen delivery conditions, it remained within an acceptable range, indicating that the LNP delivery system of the present invention has low cytotoxicity when co-delivering multi-antigen encoded mRNA and is suitable for the construction of multi-antigen DC vaccines.

[0152] Example 6

[0153] This embodiment provides the detection of TAA expression after LNP-encapsulated mRNA is loaded into immature dendritic cells (iDCs).

[0154] This embodiment uses immunocytochemistry (ICC) technology to evaluate the effect of the LNP delivery system on tumor antigen (TAAs) expression in dendritic cells (DCs), aiming to verify whether LNP delivery via a mixture of three mRNAs can effectively promote tumor antigen expression in DCs.

[0155] Three types of LNPs were used in the experiment, each encapsulating only one type of tumor antigen-encoding mRNA. These LNPs were co-incubated with dendritic cells (DCs) for 18 hours, with a delivery dose of 1 μg mRNA / 1 × 10⁻⁶ LNPs. 6 iDCs. Antigen expression in DCs was detected using immunocytochemistry (ICC). Cell nuclei were labeled with DAPI staining, and specific antibodies against the target antigens were used for labeling. Merged images were used to visualize the intracellular localization and expression of the antigens.

[0156] The detection results are shown in Figure 4. Immunocytochemistry (ICC) was used to successfully observe the expression of the target antigen after mRNA delivery in DCs.

[0157] The delivery dose was 1 μg mRNA / 1×10 6 Under DC conditions, the expression of antigens is as follows:

[0158] DAPI staining is used to label cell nuclei, which exhibit blue fluorescence.

[0159] The antibody labeling of the target antigen showed localized expression of the antigen within DCs, with a clear red fluorescent signal.

[0160] The merged image showed colocalization of antigen expression with the cell nucleus, further confirming mRNA delivery and successful antigen expression.

[0161] This experiment demonstrates that the LNP delivery system can effectively deliver mRNA to DCs and induce the expression of the target antigen. Although only 1 μg mRNA / 1 × 10⁻⁶ was used... 6 Despite the low delivery dose of DCs, significant antigen expression was still observed, indicating that the system maintains strong delivery efficiency even at low doses. Antigen expression levels may further increase with increasing delivery dose.

[0162] This experiment verified the ability of the LNP delivery platform to effectively express multiple tumor antigens in dendritic cells, indicating that this technology has broad application prospects in anti-tumor immunotherapy, especially in the development of dendritic cell vaccines.

[0163] Example 7

[0164] This embodiment provides the detection of expression of DC maturation-related surface markers after LNP-encapsulated mRNA is loaded into immature dendritic cells (iDCs).

[0165] The mixed delivery of three mRNAs, LNP, facilitates the maturation and activation of immature dendritic cells (iDCs) induced by tumor antigens (TAAs) in dendritic cells (DCs).

[0166] This embodiment aims to evaluate the ability of three mRNAs delivered in combination with LNPs to induce phenotypic maturation and functional activation in immature dendritic cells (iDCs). In the experiment, the three LNPs used encapsulated mRNAs encoding three tumor-associated antigens (TAAs), namely MUC-1, NY-ESO-1, and WT-1, with each LNP encapsulating only one mRNA.

[0167] During the experiment, the three LNPs were mixed in proportion and added to iDCs for 18 hours of co-incubation. The total mRNA delivery dose for each TAA was set at 0.5 μg, 1.0 μg, and 2.0 μg (based on the amount of encapsulated mRNA, all per 1×10⁻⁶ mRNA). 6 DCs were incubated and then flow cytometry was used to detect maturation and activation markers (including CD80, CD86, CD40, CD83, CD54, and HLA-ABC) and migration-related indicators (CCR7, CXCR4 expression and chemotaxis) of DCs.

[0168] The results are shown in Figure 5. The expression of maturation marker molecules on the surface of dendritic cells was assessed by median fluorescence intensity (MFI).

[0169] In Figure 5, A represents CD80: Negative control: 1023; Positive control: 2844; 0.5 μg group: 1738; 1.0 μg group: 1957; 2.0 μg group: 1858;

[0170] In Figure 5, B represents CD86: negative control: 257; positive control: 1035; 0.5 μg group: 805; 1.0 μg group: 989; 2.0 μg group: 980.

[0171] In Figure 5, C represents CD40: Negative control: 815; Positive control: 2982; 0.5 μg group: 1898; 1.0 μg group: 2175; 2.0 μg group: 1987.

[0172] In Figure 5, D represents HLA-ABC: negative control: 4596; positive control: 8856; 0.5μg group: 6606; 1.0μg group: 7411; 2.0μg group: 6264.

[0173] In Figure 5, E represents CD54: Negative control: 690; Positive control: 8441; 0.5 μg group: 7333; 1.0 μg group: 8968; 2.0 μg group: 7112.

[0174] In Figure 5, F represents CD83: negative control: 723; positive control: 1234; 0.5 μg group: 1479; 1.0 μg group: 2377; 2.0 μg group: 1681.

[0175] The data above indicate that the combined delivery of LNP with three mRNAs can effectively induce the phenotypic transformation of iDCs to mature DCs. In particular, at a dose of 1.0 μg, the expression of multiple maturation-related markers reached levels close to or exceeding those of the positive control, indicating that this dose has a superior effect in inducing DC maturation.

[0176] Example 8

[0177] This embodiment provides an analysis of the expression levels and chemotactic ability of DC migration-related surface markers after LNP-encapsulated mRNA is loaded into immature dendritic cells (iDCs).

[0178] Figure 6 shows the analysis results of expression levels and chemotactic ability of DC migration-related surface markers after co-culturing iDCs and LNPs (mRNA-TAAs) for 18 hours.

[0179] In Figure 6, A represents CCR7 (MFI): Negative control: 661; Positive control: 1936; 0.5 μg group: 1181; 1.0 μg group: 1340; 2.0 μg group: 1122.

[0180] In Figure 6, B represents CXCR4 (MFI): Negative control: 492; Positive control: 1570; 0.5 μg group: 1069; 1.0 μg group: 1313; 2.0 μg group: 1296.

[0181] In Figure 6, C represents chemotaxis (%): negative control: 23.1%; positive control: 50.9%; 0.5 μg group: 46.4%; 1.0 μg group: 44.8%; 2.0 μg group: 43.2%.

[0182] The above results further demonstrate that the mixed delivery of LNPs from the three mRNAs not only induced the phenotypic maturation of iDCs, but also enhanced their migration-related functions, including the expression of chemokine receptors and actual chemotaxis, which is of great significance for their migration to lymphoid tissues in vivo and their function of antigen presentation.

[0183] This experiment demonstrates that LNP-encapsulated mRNA encoding TAAs can effectively induce the maturation and activation of dendritic cells (DCs) in vitro and activate their immune migration function, providing strong support for the application of the LNP delivery platform in the development of dendritic cell vaccines.

[0184] Example 9

[0185] This embodiment provides functional verification of LNP-modified dendritic cells delivered by a mixture of three mRNAs in activating T cells.

[0186] This embodiment aims to verify whether dendritic cells (DCs) treated with LNP via a mixture of three mRNAs have the ability to effectively activate T cells.

[0187] The three LNPs used in the experiment encapsulated mRNAs encoding three tumor-associated antigens (TAAs): MUC-1, NY-ESO-1, and WT-1, respectively, with each LNP encapsulating only one type of mRNA. The three LNPs were mixed in a specific ratio and incubated with immature dendritic cells (iDCs) for 18 hours. The total mRNA delivery dose for each TAA was set at 0.5 μg, 1.0 μg, and 2.0 μg (calculated based on encapsulated mRNA, all per 1 × 10⁻⁶ mRNA). 6 (Number of DCs).

[0188] After LNP incubation, the treated DCs were co-cultured with autologous T cells at a ratio of 1:10 for 72 hours. Subsequently, the activation status of T cells was detected, including the secretion levels of early activation marker CD69, late activation marker CD25, cytokine IFN-γ, and T cell proliferation capacity.

[0189] Figure 7 shows the results of T cell activation marker expression analysis after co-culturing DC-loaded LNP-encapsulated mRNA (mRNA-TAAs) with T cells for 72 hours. The expression of T cell activation markers was detected by flow cytometry, and the results are as follows:

[0190] In Figure 7, A represents CD69 expression: Control T cell group: 5.3%; mDC (positive control) + T cells: 8.9%; DC-LNP + T cells: 0.5 μg group: 6.5%; 1.0 μg group: 10.7%; 2.0 μg group: 5.8%.

[0191] In Figure 7, B represents CD25 expression: Control T cell group: 4.5%; mDC (positive control) + T cells: 22.8%; DC-LNP + T cells: 0.5 μg group: 20.4%; 1.0 μg group: 22.1%; 2.0 μg group: 17.7%.

[0192] The above results indicate that DCs treated with LNP-delivered mRNA can effectively induce T cell activation. In particular, in the 1.0 μg group, the expression levels of CD69 and CD25 in T cells were significantly increased, approaching or reaching the levels of the positive control group.

[0193] Figure 8 shows the analysis results of the interferon-γ (IFN-γ) secretion level after T cells were co-cultured with DCs loaded with LNP-encapsulated mRNA (mRNA-TAAs) for 72 hours. The ability of T cells to secrete interferon-γ (IFN-γ) was detected by ELISA and ELISpot methods:

[0194] Figure 9A shows the IFN-γ levels detected by ELISA: Control T cell group: 36.5 pg / mL; mDC (positive control) + T cells: 821.8 pg / mL; DC-LNP + T cells: 0.5 μg group: 561.4 pg / mL; 1.0 μg group: 794.6 pg / mL; 2.0 μg group: 446.6 pg / mL.

[0195] In Figure 9, B represents the number of spots detected by ELISpot: Control T cell group: 31; mDC (positive control) + T cells: 619; DC-LNP + T cells: 0.5μg group: 409; 1.0μg group: 542; 2.0μg group: 387.

[0196] The results showed that LNP-modified DCs could effectively induce T cells to secrete IFN-γ, and the secretion level of the 1.0 μg dose group was close to that of the positive control group in both detection methods.

[0197] Figure 9 shows the results of T cell viability and proliferation analysis after co-culturing DC-loaded LNP-encapsulated mRNA (mRNA-TAAs) with T cells for 72 hours. T cell proliferation capacity was assessed using the MTT assay.

[0198] OD490 values: Control T cell group: 1.5; mDC (positive control) + T cells: 3.0; DC-LNP + T cells: 0.5μg group: 2.5; 1.0μg group: 2.8; 2.0μg group: 2.4.

[0199] These results further demonstrate that DCs treated with LNP via a mixture of three mRNAs effectively promote T cell proliferation, with the 1.0 μg dose group showing the best performance.

[0200] In summary, the combined delivery of LNPs from three mRNAs can endow dendritic cells (DCs) with significant antigen presentation and T cell activation capabilities in vitro, providing strong technical support for the clinical translation of dendritic cell vaccines in tumor immunotherapy.

Claims

1. An LNP-encapsulated mRNA delivery system for antigen-presenting cells, characterized in that, The system includes lipid nanoparticles and at least one mRNA encoding a tumor-associated antigen, wherein the mRNA is encapsulated in the lipid nanoparticles; the lipid nanoparticles include ionizable cationic lipids, DSPC, cholesterol, and PEG2000 conjugated lipids.

2. The LNP-encapsulated mRNA delivery system for antigen-presenting cells according to claim 1, characterized in that, The ionizable cationic lipids include SM102, DLin-MC3-DMA, A15-1, or other similar compounds.

3. The LNP-encapsulated mRNA delivery system for antigen-presenting cells according to claim 2, characterized in that, The molar ratio of the ionizable cationic lipid, DSPC, cholesterol, and PEG2000 conjugated lipid is 50:10:38.5:1.

5.

4. The LNP-encapsulated mRNA delivery system for antigen-presenting cells according to any one of claims 1-3, characterized in that, The tumor-associated antigen is selected from one or more of mucin 1, New York esophageal squamous cell carcinoma 1, or Wilms tumor 1.

5. The LNP-encapsulated mRNA delivery system for antigen-presenting cells according to claim 4, characterized in that, The delivery system also includes a cryoprotectant selected from one or more of sucrose, sucrose, glucose, or glycerol.

6. A method for preparing an LNP-encapsulated mRNA delivery system for antigen-presenting cells according to any one of claims 1-5, characterized in that, The method includes the following steps: Ionizable cationic lipids, DSPC, cholesterol, and PEG2000 conjugated lipids were dissolved in ethanol at a molar ratio to form an organic phase; The mRNA was placed in sodium acetate buffer to form an aqueous phase; The organic phase and the aqueous phase were combined at a volume ratio of 3:1 using microfluidic polymerization technology, with the total flow rate maintained at 6 mL / min.

7. The method for preparing the LNP-encapsulated mRNA delivery system for antigen-presenting cells according to claim 6, characterized in that, The method also includes purification and refining, specifically including: After the nanoparticles were formed, the LNPs were dialyzed three times consecutively using sterile PBS that did not contain divalent cations, with a 3.5 kDa molecular weight cutoff dialysis kit used for the dialysis. After dialysis, the solution was subjected to centrifugation and ultrafiltration using a 30 kDa MWCO filter.

8. The use of any one of the LNP-encapsulated mRNA delivery systems for antigen-presenting cells according to claims 1-5 in the preparation of mRNA-loaded antigen-presenting cells.

9. The application according to claim 8, characterized in that, The antigen-presenting cells are DC cells; the application includes adding an LNP-encapsulated mRNA delivery system for antigen-presenting cells to cultured immature dendritic cells.

10. The application according to claim 9, characterized in that, Immature dendritic cells were co-cultured with the LNP-encapsulated mRNA delivery system for antigen-presenting cells for 18–20 h; and / or the amount of LNP-encapsulated mRNA delivery system added to the antigen-presenting cells was 0.5–2.0 μg per tumor-associated antigen, based on the encapsulated mRNA.